There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 4 | 22 | 885.05 |
| 5 | 78 | 885 |
| 1 | 9 | 884.95 |
| 2 | 2 | 884.9 |
| 5 | 129 | 884.85 |
| Ask | Qty | Orders |
|---|---|---|
| 885.55 | 3 | 8 |
| 885.6 | 2 | 21 |
| 885.65 | 2 | 5 |
| 885.7 | 3 | 24 |
| 885.75 | 3 | 10 |
Price to Earning Ratio,is 13.81, lower than its sector PE ratio of 47.08.Interest Coverage Ratio,is 47.25, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).Debt to Equity Ratio,of 0.08 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Natco Pharma Limited is a vertically integrated and RD focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
It is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.
The intraday high for Natco Pharma Ltd on the NSE today (24 Aug 2026) was ₹892.35. This compares to the 52-week high of ₹1,226.80 recorded on 12 May 2026. Today's high was -27.26% below the 52-week high.
For Q1 FY27, Natco Pharma Ltd reported: Revenue (Net Sales): ₹5966.00 Cr - Down -2.00% year-on-year from ₹6088.00 Cr in Q4 FY26. Net Income (PAT): ₹746.00 Cr - Down -64.41% year-on-year from ₹2096.00 Cr in Q4 FY26.
Natco Pharma Ltd has delivered a return of -24.77% over the last 3 months. The stock was trading at ₹1,173.00 on 25 May 2026 and is currently at ₹885.00 as of 24 Aug 2026, reflecting a Loss of ₹288.00 per share over this period.
Natco Pharma Ltd has delivered 0.86% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,226.80 on 12 May 2026 and a 52-week low of ₹789.00 on 30 Sep 2025. It is currently trading at ₹885.00 as of 24 Aug 2026.
The all-time high (ATH) for Natco Pharma Ltd was ₹1,592.85, recorded on 12 Sep 2024. At the current price of ₹885.00, the stock is trading 44.44% below its all-time high. The all-time low recorded was ₹22.28 on 05 Feb 2010.
Natco Pharma Ltd has delivered a -1.83% absolute return over the past 5 years, equivalent to a CAGR of -0.37% per annum. The stock was priced at ₹901.50 in Aug 2021 and has fallen to ₹885.00 as of 24 Aug 2026. An investment of ₹1,00,000 in Natco Pharma Ltd five years ago would be worth ₹98,170.00 today.
Yes,Natco Pharma Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 29.50 per share between FY2022 and FY2026, with the most recent dividend of ₹1.50 per share for Aug 26, with an ex-dividend date of 20 Aug 2026. At the current market price of ₹885.00, the trailing dividend yield of Natco Pharma Ltd stands at 4.50%.
As of 24 Aug 2026, the share price of Natco Pharma Ltd is ₹885.00 on the NSE and ₹885.80 on the BSE. The stock opened at ₹884.00, touched a high of ₹892.35 and a low of ₹877.50 during today's session.
Over the last 6 months, Natco Pharma Ltd has given a return of -6.61%. The stock was priced at ₹944.85 on 24 Feb 2026 and has Fallen to ₹885.00 as of 24 Aug 2026, a change of ₹59.85 per share.
The intraday low for Natco Pharma Ltd on the NSE today was ₹877.50. The stock's 52-week low stands at ₹789.00, recorded on 30 Sep 2025. Today's low is 11.22% above the 52-week low, indicating the stock is trading well above its yearly lows.
